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the original work isObjective: We estimated the investment needs, population health gains, and cost-
effectiveness of different policy options for scaling-up prevention and treatment of HIV
in the 10 countries that currently comprise 80% of all people living with HIV in sub-
Saharan Africa (Ethiopia, Kenya, Malawi, Mozambique, Nigeria, South Africa, Tanza-
nia, Uganda, Zambia, and Zimbabwe).
Design: We adapted the established STDSIM model to capture the health system
dynamics: demand-side and supply-side constraints in the delivery of antiretroviral
treatment (ART).
Methods: We compared different scenarios of supply-side (i.e. health system capacity)
and demand-side (i.e. health seeking behavior) constraints, and determined the impact
of changing guidelines to ART eligibility at any CD4þ cell count within these con-
straints.
Results: Continuing current scale-up would require US$178 billion by 2050. Changing
guidelines to ART at any CD4þ cell count is cost-effective under all constraints tested in
the model, especially in demand-side constrained health systems because earlier
initiation prevents loss-to-follow-up of patients not yet eligible. Changing guidelines
under current demand-side constraints would avert 1.8million infections at US$208 per
life-year saved.
Conclusion: Treatment eligibility at any CD4þ cell count would be cost-effective, even
under health system constraints. Excessive loss-to-follow-up and mortality in patients
not eligible for treatment can be avoided by changing guidelines in demand-side
constrained systems. The financial obligation for sustaining the AIDS response in sub-
Saharan Africa over the next 35 years is substantial and requires strong, long-term
commitment of policy-makers and donors to continue to allocate substantial parts of
their budgets. Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 30:2341–2350Keywords: cost-effectiveness, health system constraints, HIV prevention, HIV
treatment, investment needs, mathematical modeling, sub-Saharan Africa Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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2342 AIDS 2016, Vol 30 No 15IntroductionThe fight against HIV in sub-Saharan Africa (SSA) has a
strong momentum with the scale-up of treatment and
prevention interventions. The number of people receiv-
ing antiretroviral treatment (ART) has increased from less
than 100 000 in 2004 to almost 12 million in 2015 [1],
vastly improving life-expectancy of the general popu-
lation [2]. Yet, despite these impressive achievements, the
HIVepidemic is still very much an unfinished agenda. By
2015, the number of people living with HIV in the world
had risen to 37 million, of which 70% were in SSA [1].
ART provision in SSA is still suboptimal due to
constraints on both the demand-side (i.e. the population
level demand for HIV care) and the supply-side (i.e. the
capacity of the health system to meet population need)
[3,4]. HIV incidence in SSA remains high [5], and the
success of ART means increasing numbers of people
require long-term treatment and care [6,7]. Long-term
financial commitments through both donor contri-
butions and increased domestic funding of treatment
programs are therefore critical if the fight against HIV is to
be sustained and further expanded [8–11].
Because ART not only extends and improves the lives of
HIV-infected people, but also substantially reduces their
infectiousness [12,13], expanding access to treatment will
benefit both the HIV-infected and HIV-uninfected
populations [14–17]. The WHO released guidelines
for HIV treatment in mid-2013, recommending
threshold for ART initiation to be raised from CD4þ
cell counts of 350 cells/ml or less to 500 cells/ml or less
[17]; and in 2015 the WHO released updated treatment
guidelines (http://www.who.int/hiv/pub/arv/policy-
brief-arv-2015/en/), recommending that ART should
be initiated at any CD4þ cell count. Providing ART at
any CD4þ cell count could simplify HIV care delivery in
SSA, as triaging according to CD4þ cell count or disease
stage is no longer needed, and the relatively high rates of
loss-to-follow-up and associated mortality in pre-ART
care could potentially be avoided [18]. In addition, the
Strategic Timing of Antiretroviral Treatment (START)
trial recently showed that initiation of ARTat CD4þ cell
counts of more than 500 cells/ml results in health benefits
for the individual patient [19].
Mathematical modeling can assist policy-makers in
SSA and donors globally to better understand future
obligations and the impact of future funding for HIVand
therebymake informed decisions in budget allocation and
ART treatment guidelines development. We have
recently provided estimates of the investment needs for
the HIV in nine SSA countries and shown that there are
still substantial funding gaps in place [20], raising
questions on the optimal policy choices in ART scale-
up in countries faced with health system constraints.
Therefore, a comprehensive evaluation of the cost-
effectiveness and resource needs of different policy Copyright © 2016 Wolters Kluwer Hoptions is needed – both on tackling supply-side and
demand-side constraints as well as changing guidelines to
treat HIV-infected people at any CD4þ cell count within
existing constraints.
We used the established STDSIM model [7,16,21–23],
and expanded the model for this study to capture the
underlying dynamics of demand-side and supply-side
interactions of ART delivery that ultimately determine
ART coverage, to estimate the future investment needs,
population health gains, and cost-effectiveness for a wide
range of policy options for the AIDS response in Ethiopia,
Kenya, Malawi, Mozambique, Nigeria, South Africa,
Tanzania, Uganda, Zambia, and Zimbabwe. These
countries account for about 80% of the current HIV
burden in SSA [5]. We compared different scenarios of
supply-side and demand-side constraints in ART delivery
and determined the impact of changing ARTeligibility at
any CD4þ cell count for these scenarios.Methods
STDSIM is a stochastic microsimulation model that
simulates individuals in a dynamic network of sexual
contacts [16]. The model incorporates health system
constraints on both the supply-side and demand-side of
HIV prevention, treatment, and care, allowing for more
realistic projections of the effects of different ART
treatment scale-up scenarios. We used previously
published country level quantifications for the 10
countries [7], and we updated and refined these country
level fits to accurately reflect updated epidemiological and
ART uptake data [5].
Model and fitting
In the model, HIV is described in four consecutive stages
with exponentially distributed durations: early infection,
asymptomatic infection, symptomatic infection, and
AIDS. Average survival of an individual with untreated
HIV is about 10 years [24]. ART treatment uptake in the
model is the result of two submodels. The first represents
an individual’s demand for ART as a function of disease
stage, whereas the second describes the health systems
capacity to meet population need [25].
For the purpose of this study, we updated and refined
previously published country quantifications of STDSIM
for Ethiopia, Kenya, Malawi, Mozambique, Nigeria,
South Africa, Tanzania, Uganda, Zambia, and Zimbabwe
[7]. A more detailed description of the model, our
approach, and the resulting fit of model projections to
data are described in the Supplementary material (http://
links.lww.com/QAD/A948).
Scenarios
Wemodeled six scenarios reflecting pessimistic (scenarios
1 and 2), realistic (scenarios 3), and optimistic (scenariosealth, Inc. All rights reserved.
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side constraints are progressively removed in scenarios 1
to 4 keeping demand-side constraints intact; whereas
demand-side and supply-side constraints are removed in
scenarios 5 and 6. For each scenario, we modeled two
ARTeligibility thresholds (ART at CD4þ cell counts of
500 cells/ml or less and ART at any CD4þ cell count).
The scenarios are as follows:(1) Current financing obligations – continue treating patients
who are currently on treatment; no other people are
initiated on treatment as of 1 January 2016 ( pessimistic
scenario).(2) Health system constraints – the number of people on ART
as of 1 January 2016 is maintained; people can only
initiate treatment when slots free-up because of
mortality or loss-to-follow-up ( pessimistic scenario –
supply-side and demand-side constraints).(3) Continued scale-up – current rate of treatment scale-up
continues into the future until all supply-side constraints
are removed (realistic scenario – demand-side constraints).(4) Rapid scale-up – All supply-side constraints are removed
per 1 January 2016 (optimistic scenario – demand-side
constraints).(5) 90-90-90; target set by The Joint United Nations
Programme on HIV/AIDS (UNAIDS) [26] – all
supply-side constraints are removed per 1 January 2016
annual population-based screening for HIV at 90%
coverage removes demand-side constraints. All HIV-
infected people participating in screening are linked to
care and initiated on ART when eligible (optimistic
scenario – no constraints).(6) Expanded 90-90-90 (90-90-90þ) – scale-up of the
following prevention services next to the 90-90-90
scenario (optimistic scenario – no constraints): male
circumcision (80% coverage), condom distribution
(non-use reduced by 60%), behavior change (overall
partner change rates reduced by 10%), and prevention of
mother-to-child transmission (95% coverage). Details
are in Supplementary material Section 2.5, http://
links.lww.com/QAD/A948.Costs
We derived unit costs for treatment-related services by
combining data from the multicountry analysis of
treatment costs for HIV/AIDS study [27] and Menzies
et al. [28].We set the cost of first-line antiretrovirals cost at
US$132 per person per year (2012 USD) [27], and
second-line antiretrovirals at US$366 (2013 USD) [29].
All ART treatment costs were further increased by 20% to
account for above facility programmatic costs [30]. We
determined costs from the healthcare provider perspect-
ive, and did not include medical costs incurred offsite (i.e.
inpatient days), patient time, and patient travel costs.
Cost-effectiveness of strategies and scenarios was calcu-
lated as the cost in US$ per life-year saved, and we applied
traditional willingness to pay threshold values in terms of
Gross Domestic Product (GDP) per capita income. Copyright © 2016 Wolters KluweRapidly scaling up ART treatment access by relaxing
supply-side constraints will require upfront investments in
health system improvements. Therefore, we calculated a
once-off cost reflecting health system improvements
when needed, with data derived from National AIDS
Spending Assessment country reports [31]. More details
on all cost assumptions are given in the Supplementary
material Section 3 and Table S5, http://links.lww.com/
QAD/A948.Results
Figure 1 shows the predicted number of people living
with HIV, new HIV infections, people on ART, and life-
years saved in the 10 countries for the six scenarios under
guidelines of ARTeligibility at CD4þ cell counts of 500
cells/ml or less (left panels) and under ART eligibility
at any CD4þ cell count (right panels). The optimistic
90-90-90þ scenario provides the largest impact on
incidence: from 320 000 per year to only 27 000 (under
ART at CD4þ cell counts of 500 cells/ml or less) and
22 000 new infections (under ART at any CD4þ cell
count). Because demand-side constraints limit the
number of people initiating treatment with high CD4þ
cell counts, the number of people on treatment when
offering ART at any CD4þ cell count is only slightly
higher compared with ART eligibility at CD4þ cell
counts of 500 cells/ml or less in scenarios 1–4.
Annual investment needs peak at about US$11 billion for
the expanded 90-90-90 scenario under ARTeligibility at
any CD4þ cell count and are between US$6 and US$8
billion for continued (scenario 3) and rapid scale-up
(scenario 4) of health systems access (Fig. 2).
Removing heath system constraints
Cumulative total investment needs, population health
gains, and cost-effectiveness (compared with scenario 1)
when removing health system constraints are shown in
Table 1. Continued scale-up of ARTwith demand-side
constraints remaining in place (scenario 3) would need an
investment of US$178 billion and would result in about
11 million infections averted and 377 million life-years
saved by 2050 (ICER: 272 US$/life-year saved).
Removing both supply-side and demand-side constraints
(scenario 5) would need an investment of US$186 billion,
resulting 13 million infections averted and 424 million
life-years saved. The most cost-effective option is to also
scale-up HIV prevention interventions (scenario 6) with
slightly lower investment needs compared with scenario
5 (US$165 billion) yet more infections averted (about
20 million) and life-years saved (about 493 million).
Changing eligibility guidelines
The annual incremental investment needs and life-years
saved of changing guidelines from ART at CD4þ cellr Health, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 1. Predicted trends in number of people living with HIV, new HIV infections, people on antiretroviral treatment, and life-
years saved (compared with the liability scenario) over the period 2015–2050 for the 10 countries with the largest HIV
epidemics in sub-Saharan Africa. The HIV burden in 2015 was divided over the 10 countries as follows: 31% in South Africa, 16%
in Nigeria, 8% in Uganda, 8% in Mozambique, 7% in Tanzania, 7% in Kenya, 7% in Zimbabwe, 5% in Zambia, and 3% in
Ethiopia.
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Fig. 2. Average annual HIV treatment and prevention costs in the 10 countries with the largest HIV epidemic in sub-Saharan
Africa. Costs include antiretroviral treatment costs, circumcision, condom distribution, and prevention of mother-to-child
transmission (PMTCT) screening and treatment for Ethiopia, Kenya, Malawi, Mozambique, Nigeria, South Africa, Tanzania,
Uganda, Zambia, and Zimbabwe. Costs and effects are discounted at an annual rate of 3%. Treatment costs represent about 80%of
all costs, followed by PMTCT (12%), male circumcision (5%), condom distribution (2%), and behavior change (1%).counts of 500 cells/ml or less to ART at any CD4þ cell
count within each scenario of health system constraints
are shown in Fig. 3. The incremental investment needs for
changing guidelines are highest in the 90-90-90 and 90-
90-90þ scenarios (about US$1.6 billion each year),
whereas in the continued scale-up scenario, only
relatively modest upfront investments of about US$700
million annually are needed, an increase of about 10%.
Importantly, changing guidelines in scenarios in which
demand-side constraints are still in place (realistic
scenarios) will result in more life-years saved (about
1.2 and 1.4 million additional life-years saved for
continued and rapid scale-up, respectively) compared
with the optimistic scenarios in which supply-side and
demand-side constraints are removed completely (0.2 to
0.6 million life-years saved for 90-90-90 and 90-90-90þ
scenarios, respectively) (Fig. 3). This effect occurs because
refusing people treatment at CD4þ cell counts of more
than 500 cells/ml in demand-side constrained systems will
often result in patients defaulting pre-ART care and
subsequent late presentation or mortality. These detri-
mental effects are prevented when people are initiated at
any CD4þ cell count. In a system with no constraints
(e.g., the 90-90-90 scenario), these people will still be
initiated as soon as their CD4þ cell counts drop below
500 cells/ml, making the incremental benefit of initiation
at any CD4þ cell count less profound.
The cost-effectiveness of changing eligibility to ART at
any CD4þ cell count ranges from US$54 per life-year
saved under health systems constraints to US$1358 per
life-year saved for the 90-90-90þ scenario (Table 2).
Even under our most conservative willingness to pay
threshold, changing guidelines is cost-effective in all
scenarios except for the 90-90-90þ scenario. Never-
theless, changing guidelines under severe supply-side Copyright © 2016 Wolters Kluweconstraints would result in a loss of about 4.6 million life-
years because healthier patients are crowding out patients
with more advanced disease. Alternative assumptions on
health-seeking behavior had a limited impact on these
results (Table S6, http://links.lww.com/QAD/A948).Discussion
Continuation of the AIDS response in SSA over the
period 2016–2050 will require substantial investment
needs. Under eligibility criteria of ART at CD4þ cell
counts of 500 cells/ml or less, annual investment needs
between 2016 and 2020 in the 10 countries that share
80% of the HIV burden in SSA range from about US$5
billion in the undesirable pessimistic scenario of only
treating patients currently on ART to about US$7–8
billion if health system access is continuously improved.
Total investment needs through to 2050 under continued
scale-up would amount to about US$180 billion.
Changing guidelines to provide ART at any CD4þ cell
count is highly cost-effective in all scenarios, especially in
scenarios with demand-side constraints. However,
providing ART at any CD4þ cell count under supply-
side constraints will result in population health loss, as
healthy patients are crowding out people with advanced
disease.
To our knowledge, this study is the first that shows the
effects of changing guidelines to treating HIV-infected
people at any CD4þ cell count within realistic scenarios
of health systems that are experiencing supply-side and
demand-side constraints. Previous modeling studies have
shown that universal test and treat can substantially reduce
HIV incidence [14,16,32], yet these studies all relied on
optimistic scenarios of high levels of treatment uptake,r Health, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 3. Incremental costs and life-years of changing guidelines from antiretroviral treatment at CD4R cell counts of 500 cells/ml
or less to antiretroviral treatment at any CD4R cell count in the 10 countries with the largest HIV epidemic in sub-Saharan
Africa, for five scenarios. Guidelines are changed to HIV infected people at any CD4þ cell count, within each health system
constraint scenario in 2016. The liability scenario is not included since no new people will be initiated on antiretroviral treatment
after 2016 in this scenario, so a guidelines change will have no net effects. Costs and effects are discounted at an annual rate of 3%.similar to our 90-90-90 scenarios.We show that changing
eligibility guidelines to ARTat any CD4þ cell count in a
health system with demand-side constraints has more
benefits (about 20million life-years saved) compared with
scenarios of universal test and treat (5 to 10 million life-
years saved), whereas initial investment needs are only a
modest 10% higher compared ART eligibility at CD4þ
cell counts of 500 cells/ml or less.
There are currently several large-scale community
randomized trials underway that examine the feasibility
and impact of the concept of treatment as prevention in a
real-world settings [33,34]. Although these studies are
valuable in assessing the potential impact and feasibility of Copyright © 2016 Wolters Kluwe
Table 2. Investment needs, population health gains, and cost-effectivene
antiretroviral treatment at CD4R cell counts of 500 cells/ml or less to antir
with the largest HIV epidemics in sub-Saharan Africa.
ART eligibility at any
Scenario Constraints
Investment needs
Incremental cost
(million US$) (range) t
2. Health systems
constraints
Supply-side and
demand-side
(pessimistic)
246 (224; 271) 0
3. Continued scale-up Only demand-side
(realistic)
3979 (3530; 4496) 1
4. Rapid scale-up Only demand-side
(optimistic)
2555 (2276; 2877) 1
5. 90-90-90 No constraints
(optimistic)
2184 (1950; 2451) 1
6. 90-90-90þ None (optimistic) 7463 (6747; 8165) 0
Ranges are shown between brackets and reflect uncertainty in model fit parameters
sexually transmitted HIV, vertical infections reflect mother-to-child transmission of HIV
only continued for all currently receiving ART, and there are no new imitations after 20
effect on costs and population health. ART, antiretroviral treatment; ICER, incremena universal test and treat approach [35], we show that
health system constraints may provide sufficient ground
to change guidelines. Triaging HIV treatment is
becoming increasingly complex, with different consider-
ations by CD4þ cell count, HIV disease stage, pregnancy
status, coinfections with tuberculosis or hepatitis, and the
HIV status of a cohabiting sexual partner. Providing
treatment at any CD4þ cell count will substantially
simplify treatment delivery in settings with weak health
systems and thus improve efficiency. In addition, high
rates of loss-to-follow-up in patients that are referred to
pre-ART care because their HIV status does not match
with eligibility criteria could be avoided. Furthermore,
the START trial showed that earlier treatment initiationr Health, Inc. All rights reserved.
ss of changing antiretroviral treatment treatment guidelines from
etroviral treatment for all HIV-infected people – in the 10 countries
CD4þ cell count vs. ART eligibility at CD4þ cell count 500 cells/ml
Population health gains Cost-effectiveness
Infections averted
(million) (range)
Life-years saved
(million) (range)
ICER (costs in US$ per
life year saved) (range)
Horizontal
ransmission
Vertical
transmission
.5 (0.4; 0.8) 0.1 (0.1; 0.1) 4.6 (4.7; 4.4) 54 (51; 57)
.6 (1.0; 2.2) 0.2 (0.1; 0.3) 19.2 (18.4; 19.8) 208 (191; 227)
.5 (1.0; 2.3) 0.2 (0.1; 0.3) 22.4 (21.5; 23.2) 114 (106; 124)
.5 (0.9; 2.5) 0.1 (0.1; 0.2) 10.0 (9.6; 10.3) 219 (203; 237)
.5 (0.4; 0.6) 0.1 (0.0; 0.1) 5.5 (5.3; 5.7) 1358 (1276; 1435)
(see Supplementary material for more details). Horizontal infections represent
. The liability scenario is not shown, because in this pessimistic scenario ART is
16. Hence, changing guidelines to ART at any CD4þ cell count would have no
tal cost-effectiveness ratio.
2348 AIDS 2016, Vol 30 No 15would also result in improved treatment outcomes in
individual patients as well [19].
Regardless of changes in guidelines and future scenarios,
our results show that continued fight against HIV will
require substantial investments over the coming decades.
However, the economic climate is challenging, and
international funding for HIV is flat lining [36].
Innovative funding sources must be considered [37],
along with improvements in health system efficiency and
better allocation of available resources to meet future
financing obligations.
Our results show that scaling up prevention interventions
along with expansion of ART is highly beneficial. The
added value of increased rates of circumcision, condom
use, prevention of mother-to-child transmission
(PMTCT), and lower rates of partner change in our
90-9090 scenario is about 6 million averted adult
infections, 800 000 averted child infections, and 70
million life-years saved by 2050, and about US$300
million of cost-savings. Although there is an ethical
obligation to provide treatment for all HIV-infected
patients in need, our results present a strong case of
continuous investments in other prevention interventions
alongside treatment scale-up.
Our long-term predictions are subject to the assumption
that future transmission dynamics, interventions, and
other factors will remain the same. However, it is likely
that this will not be the case. Our study did not include
the investment needs and population health gains of a
PrEP roll-out in SSA because of limited available data on
potential strategies and scenarios. However, PrEP may
well be added to the mix of HIV prevention in SSA in the
near future [38]. In addition, there have been substantial
advances in search of an HIV vaccine and cure [38], and
future discoveries might affect the long-term HIV
response. Further, other unforeseeable dynamics – such
as large-scale behavior changes, or the general economic,
demographic, and social context in SSA might influence
future HIV transmission dynamics, making long-term
model predictions necessarily imprecise. Nevertheless,
these factors will likely influence all scenarios in our
analysis in a similar fashion and may therefore not change
our main conclusions substantially.
Some simplifications in our study should be taken into
account. First, due to a lack of data, unit costs in our
analysis were assumed to follow linear functions according
to program scale-up. This might not be the case in real
life, as scaling-up large-scale programs is subject to
economies of scale in which per patient costs decrease as
fixed costs of a program are spread across progressively
more patients [39,40]. Further, the cost of antiretroviral
drugs could potentially further decline in the future [41].
We also did not account for the efficiency benefits of
removing triaging and pre-ART care from ART delivery Copyright © 2016 Wolters Kluwer Hbecause limited availability of data prevented us from
incorporating these effects. Contrastingly, it may also be
possible that reaching additional patients is more costly
and less efficient because they are harder to reach and are
likely to perform poorest in treatment programs,
potentially offsetting efficiency gains because of scale
effects and declining unit costs. Second, we applied a
simple additional cost reflecting increased health worker
training and infrastructural development needed to
reduce supply-side constraints. As the required personnel
might not be readily available and requires years of
training, short-term staff increases may also require
diverting healthcare workers from other services or
pulling them from the private sector, requiring additional
funding. Due to limited data availability, we were unable
to incorporate these costs and may therefore have slightly
underestimated the costs for health system improvements
in the first years of our projections, yet this will have
limited impact on our overall projections. In addition,
scarcity of human resources for health might limit short-
term implementation of more optimistic scenarios
entirely [42] and require innovative interventions such
as task-shifting of community-based service delivery.
Third, we could not take potential negative outcomes of
changing guidelines, such as poorer adherence of
healthier patients or transmission of drug resistant strains,
into account due to lack of available data. Fourth, we did
not include below-facility costs incurred by patients
through patient time and patient travel costs [43], yet the
main focus of our study was to inform public-sector
spending decisions. Fifth, some of our scenarios might be
unrealistic. Especially our most pessimistic scenario, in
which no new patients initiate treatment, is unlikely to
happen in any country. However, we think that
comparing our more realistic scenarios with this
pessimistic scenario illustrates both the continued
investment needs as well as the health benefits of
continuing the fight against HIV. Furthermore, immedi-
ate implementation of our most optimistic scenarios
seems unlikely, as resource constraints would require
more gradual scale-up. Sixth, supply-side and demand-
side constraints in our model only affect the total number
of people on ARTand do not reflect the potential effects
on reduced rates of viral suppression among those
on ART.
We considered an international benchmark on the basis of
GDP per capita to define scenarios as (highly) cost-
effective. However, we realize that this benchmark is
poorly grounded in economic theory and therefore
somewhat arbitrary [44]. In addition, it might also be
ethically moot to let the valuation of human life depend
on per capita GDP. Nevertheless, we still consider it
convenient in the absence of local comparative cost-
effectiveness information. In addition, we compared cost-
effectiveness to several willingness to pay thresholds,
including a very conservative threshold, and our
conclusions were robust to these assumptions.ealth, Inc. All rights reserved.
Investing in the HIV response in sub-Saharan Africa Hontelez et al. 2349There have been other efforts to quantify the future
investment needs, of which the most notable are
AIDS2031, the ‘HIV Investment Framework’ Study
Group, and our recent estimates of investment needs in
nine countries [20,29,45]. The projections from these
studies are all based on the Goals model and could not
comprehensively incorporate the underlying dynamics
that determine the uptake of ART nor provide estimates
on the costs and effects ART scale-up and guideline
changes within the context of existing constraints. We
used the comprehensive microsimulation model
STDSIM, which dynamically captures HIV transmission
and the effects of interventions. In addition, rather than
assigning a coverage level of ART treatment to a certain
population at a certain point in time, our model is able to
capture the underlying dynamics of demand-side and
supply-side interactions of ART delivery that ultimately
determine ART coverage. This allows us to model the
impact of different scenarios of health system constraints
on the future developments of ART coverage instead of
making rather arbitrary assumptions on how coverage
might change in the future.
In conclusion, we show that changing guidelines to ART
eligibility at any CD4þ cell count could be a cost-
effective policy option, even when ART delivery is
subject to health system constraints. Especially in
demand-side constrained system, abandoning triaging
of ART delivery could improve efficiency and help avoid
the excessive loss-to-follow-up and mortality in patients
receiving pre-ART care. Next to ART scale-up,
investment in other prevention interventions is a
relatively low-cost commitment that could translate into
cost-savings. However, regardless of eligibility guidelines
for ARTand scale-up scenarios, the investment needs for
the AIDS response in SSA over the next 35 years are
substantial and require strong, long-term commitments of
policy-makers and donors to continue to allocate
substantial parts of their budgets to treatment and
prevention of HIV.Acknowledgements
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